View full meeting coverage »

Eyetube Meeting Coverage:

OIS RETINA 2018

 

Playing Next

Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

RFE Pharma

  Channels: Retina | Posted 7/23/2018

Alan Franklin, MD, PhD, Chief Medical Officer, RFE Pharma, provides an update on lead compound RFE-007-CAI (carboxyamidotriazole), which the company has reformulated as an anti-angiogenic intravitreal injectable formulation.

2 / 11 Series: OIS RETINA 2018